What the FDA labels say about taking them together
Adalimumab and adalimumab-adaz
Adalimumab's FDA label of October 21, 2025 names adalimumab-adaz in its boxed warning section; the adalimumab-adaz label PlainMeds reads does not name adalimumab. The adalimumab label: “If an infection develops, monitor carefully, and stop Adalimumab-adaz if infection becomes serious.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); adalimumab-adaz labels on DailyMed.
What does the adalimumab label say about adalimumab-adaz?
Adalimumab label, boxed warningSERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-adaz, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )].
Adalimumab label, drug interactionsLive vaccines: Avoid use with Adalimumab-adaz ( 5.10 , 7.3 ) * Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.
Adalimumab label, warnings and precautionsIf an infection develops, monitor carefully, and stop Adalimumab-adaz if infection becomes serious.
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the adalimumab-adaz label say about adalimumab?
Adalimumab-adaz's label (effective ) does not name adalimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label, labeler not named, effective (SPL set ), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Adalimumab-adaz | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once